
Healthcare / Pharma · NSE
Accretion Pharmaceuticals Limited, founded in 2012 and based in Ahmedabad-Sanand, Gujarat, is a pharmaceutical company active in formulations and contract manufacturing with 83 employees as of January 2025. The company offers a wide range of products including tablets, capsules, syrups, ointments, creams, medicated shampoos, dusting powders, and ayurvedic wellness products, and also provides third-party manufacturing services. The proposed fund usage mainly focuses on growth capex such as facility upgrades and new machinery to increase capacity and support exports to 20+ countries, along with working capital needs, limited debt repayment, and flexibility for general purposes, helping the company scale operations, maintain quality standards, improve liquidity, and support future expansion opportunities.
Price Band
₹101
Issue Size
₹29.75 Cr
Lot Size
1200 shares
GMP
Est. Listing
₹101
at current GMP
Subscribed
7.32x
overall
Open
14 May 2025
Close
16 May 2025
Allotment
19 May 2025
Refund
20 May 2025
Demat Credit
21 May 2025
Listing
21 May 2025
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹101
Band: ₹101
Estimated Listing Price
₹101
Upper price + GMP
Lot Size
1200 shares
Min investment ₹1,21,200
Estimated Profit / Lot
₹0
1200 × ₹0
Grey Market Premium trend
—
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | — | 0.0% | ₹101 |
| 30 Oct 2026 | — | 0.0% | ₹101 |
| 29 Oct 2026 | — | 0.0% | ₹101 |
GMP is unofficial market data. Not a guarantee of listing performance.
Accretion Pharmaceuticals Limited is bringing an initial public offering (IPO) in the Healthcare / Pharma sector with an aggregate issue size of ₹29.75 Crores. The shares are offered at a price band of ₹101 to ₹101 per equity share on NSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 1200 shares (approx. ₹1,21,200 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-05-21, while un-allotted funds or UPI block mandates will be released on 2025-05-20.
The latest grey market premium for Accretion Pharmaceuticals Limited IPO is ₹0, which indicates an expected listing price of ₹101.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.